MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals Deferred Revenue | NAVB
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 800 K | 40.8 K | 700 K | - | 867 K | - | 15 K | 1.04 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 M | 15 K | 578 K |
Quarterly Deferred Revenue Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 800 K | 800 K | 800 K | 800 K | 800 K | - | - | - | - | - | - | - | - | - | - | - | - | 495 K | - | - | - | - | - | - | - | - | 15 K | 15 K | 15 K | 682 K | 945 K | 1.04 M | 1 M | 1 M | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 736 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 M | 15 K | 684 K |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
2.94 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Bicycle Therapeutics plc
BCYC
|
2.96 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Concert Pharmaceuticals
CNCE
|
2.75 M | - | - | $ 401 M | USA |
 |
BioLineRx Ltd.
BLRX
|
3 K | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.37 M | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
BioNTech SE
BNTX
|
300 M | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Genocea Biosciences
GNCA
|
1.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Amryt Pharma plc
AMYT
|
23 M | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
620 K | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
14 K | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
12.5 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
7.01 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
1.27 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
Humanigen
HGEN
|
883 K | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
1.96 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
13.5 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
296 K | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
207 K | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
IMV
IMV
|
139 K | - | - | $ 13.1 M | Canada |
 |
Crinetics Pharmaceuticals
CRNX
|
1.24 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
667 K | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
158 K | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
1.54 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.46 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
CorMedix
CRMD
|
2.21 K | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
15.8 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
|
Champions Oncology
CSBR
|
8.83 M | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
7.57 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
6.68 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |